Certepetide is under clinical development by Lisata Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Certepetide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Certepetide overview

Certepetide (CEND-1) is under development for the treatment of solid tumors such as pancreatic cancer including pancreatic ductal adenocarcinoma, gastroesophageal junction carcinomas, triple-negative breast cancer, appendiceal cancer, breast cancer, peritoneal carcinoma, colon cancer, ovarian cancer, bile duct cancer (cholangiocarcinoma), gallbladder cancer, gastric cancer, adenocarcinoma of the gastroesophageal junction, glioblastoma multiforme, peritoneal carcinomatosis and metastatic colorectal cancer. The drug candidate is an internalized-arginylglycylaspartic acid cyclic peptide which acts by targeting neuropilin 1 receptor. It is administered through the intravenous route and is developed based on CendR Platform.

It was also under development for breast cancer, prostate cancer, non-small cell lung cancer, glioblastoma, hepatocellular carcinoma, recurrent head and neck cancer squamous cell carcinoma, appendiceal cancer oropharyngeal cancer, oral cavity (mouth) cancer, hypopharyngeal cancer, laryngeal cancer, esophageal Squamous Cell Carcinoma (ESCC) and ovarian cancer.

Lisata Therapeutics overview

Lisata Therapeutics, formerly Caladrius Biosciences Inc, is a biopharmaceutical company. It discovers and develops cellular therapies for the treatment of cardiovascular indications and autoimmune diseases. It is investigating XOWNA for the treatment of coronary microvascular dysfunction; HONEDRA against critical limb ischemia and buerger’s disease. The company is also evaluating CLBS201 for the treatment of diabetic kidney disease (DKD); and CLBS14 to treat no-option refractory disabling angina. Lisata Therapeutics utilizes its proprietary CD34+ cell therapy technology to develop therapies for ischemia diseases. It serves biotechnology, pharmaceutical and medical product companies, and academic research institutions. Lisata Therapeutics is headquartered in Basking Ridge, New Jersey, the US.

For a complete picture of Certepetide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.